NCPA has been working tirelessly to monitor the impact of the DIR hangover—and an open line to CMS has been important for us to let them know about potential PBM noncompliance with the DIR rule. You can also join the fight! If you’re observing pharmacy access issues, issues with patient harm and confusion, or issues with patient steering, CMS has a dedicated Part D Monitoring inbox at [email protected] where you can share your thoughts. (This is not for financial claim information; only for topics related to access.) So, drop them a line today — and don’t forget to cc [email protected] in your note to them. That helps us continue to help you.
NCPA
